BNY Mellon focuses on global cures with latest fund launch citywireselector.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citywireselector.com Daily Mail and Mail on Sunday newspapers.
Investment Week is hosting its Global Emerging Markets Briefing at a pivotal time for investors as they start to position for the recovery from the Covid-19 pandemic, although risks remain.
During this interactive briefing, we will hear from a number of global emerging market managers about their response to the extraordinary events of the past year and their outlook for the rest of the year and beyond.
The managers will identify where they are seeing the biggest opportunities and risks at the moment in emerging markets and explain the role their strategies could play in client portfolios.
Attendees will also get the chance to network with peers, quiz our speakers, as well as benefit from CPD points
BNY Mellon targets “cutting edge” healthcare and biotech firms
BNY Mellon Investment Management has launched a fund that targets “cutting-edge” innovation in healthcare and biotechnology.
The thematic equity fund will invest in companies developing gene therapy, gene editing and gene modulation treatments.
It also invests in biotechnology and healthcare companies that help drive the development of these drugs, according to the firm.
The fund will be managed by Amanda Birdsey-Benson and Matthew Jenkin, co-portfolio managers at Mellon with extensive experience in this area, according to the firm.
Birdsey-Benson said: “Since the completion of the human genome project in 2003, scientists have worked to discover how these genes are controlled, how they interact, and how they can cause disease. We are now at the precipice of Biotech 2.0, driven by a transformational technology inflection that should only continue to advance.”